Purple Biotech (PPBT) Intangibles (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Intangibles of $7.4 million for Q1 2026, down 73.57% year-over-year from $27.8 million in Q1 2025, and little changed quarter-over-quarter from $7.4 million in Q4 2025.
Purple Biotech (PPBT) Intangibles (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Intangibles for 10 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 73.57% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (down 73.57% YoY), while the FY2025 annual figure was $7.4 million, down 73.57% from the prior year.
- Intangibles held at $7.4 million in Q1 2026 per PPBT's latest filing, from $7.4 million in the prior quarter.
- Across five years, Intangibles topped out at $28.0 million in Q1 2023 and bottomed at -$202000.0 in Q4 2022.
- Historically, Intangibles has averaged $22.6 million across 5 years, with a median of $27.8 million in 2024.
- Annual changes were most pronounced in 2022 — Intangibles slumped 100.99% — and 2023, when it surged 13983.17%.
- Purple Biotech's Intangibles stood at -$202000.0 in 2022, then soared by 13983.17% to $28.0 million in 2023, then retreated by 0.72% to $27.8 million in 2024, then sank by 73.57% to $7.4 million in 2025, then changed by 0.0% to $7.4 million in 2026.
- Business Quant data shows PPBT's Intangibles at $7.4 million in Q1 2026, $7.4 million in Q4 2025, and $27.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 7.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.36 Mn |
| Dec 31, 2025 | 7.36 Mn |
| Sep 30, 2025 | 27.84 Mn |
| Jun 30, 2025 | 27.84 Mn |
| Mar 31, 2025 | 27.84 Mn |
| Dec 31, 2024 | 27.84 Mn |
| Sep 30, 2024 | 27.84 Mn |
| Jun 30, 2024 | 27.84 Mn |
| Mar 31, 2024 | 28.04 Mn |
| Dec 31, 2023 | 28.04 Mn |
| Sep 30, 2023 | 28.04 Mn |
| Jun 30, 2023 | 28.04 Mn |
| Mar 31, 2023 | 28.04 Mn |
| Dec 31, 2022 | -202,000.00 |
| Sep 30, 2022 | 20.68 Mn |
| Jun 30, 2022 | 20.68 Mn |
| Mar 31, 2022 | 20.68 Mn |
| Dec 31, 2021 | 20.48 Mn |
| Sep 30, 2021 | 20.48 Mn |
| Jun 30, 2021 | 20.48 Mn |